Showing posts with label MK-4827. Show all posts
Showing posts with label MK-4827. Show all posts
Tuesday, June 15, 2010
First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers (phase 1)
Results: 39 pts (male 10, female 29; median age 58 years; 11 BRCA mutation carriers) were treated...
Conclusions: MK-4827 is well tolerated, blocks PARP and has promising antitumor activity in both BRCA-deficient and sporadic cancers.
Subscribe to:
Posts
(
Atom
)
